Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 52-Week Low – Should You Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $74.26 and last traded at $74.26, with a volume of 313 shares traded. The stock had previously closed at $77.00.

Wall Street Analyst Weigh In

Several brokerages have commented on ZLDPF. William Blair upgraded Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 7th. Cantor Fitzgerald raised shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, January 21st.

Zealand Pharma A/S Stock Performance

The firm has a market capitalization of $7.02 billion, a PE ratio of -41.91 and a beta of 0.92. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average of $97.68 and a 200 day moving average of $109.51.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.19. The company had revenue of $1.30 million during the quarter, compared to analyst estimates of $28.11 million. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. Equities research analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.